It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Circulating tumor cells (CTCs) are recognized as direct seeds of metastasis. However, CTC count may not be the “best” indicator of metastatic risk because their heterogeneity is generally neglected. In this study, we develop a molecular typing system to predict colorectal cancer metastasis potential based on the metabolic fingerprints of single CTCs. After identification of the metabolites potentially related to metastasis using mass spectrometry-based untargeted metabolomics, setup of a home-built single-cell quantitative mass spectrometric platform for target metabolite analysis in individual CTCs and use of a machine learning method composed of non-negative matrix factorization and logistic regression, CTCs are divided into two subgroups, C1 and C2, based on a 4-metabolite fingerprint. Both in vitro and in vivo experiments demonstrate that CTC count in C2 subgroup is closely associated with metastasis incidence. This is an interesting report on the presence of a specific population of CTCs with distinct metastatic potential at the single-cell metabolite level.
Circulating tumor cells (CTCs) are the tumor cells responsible for metastasis. Here, the authors develop a home-built single-cell quantitative mass spectrometric platform and discover a cluster of CTCs with distinct metastatic potential using a molecular typing system based on the single-cell metabolic fingerprints.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Nanjing Medical University, School of Pharmacy, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
2 Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital), Department of General Surgery, Nanjing, China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566)
3 Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital), Department of Clinical Laboratory, Nanjing, China (GRID:grid.452509.f) (ISNI:0000 0004 1764 4566)
4 Nanjing Normal University, School of Computer Science and Technology, Nanjing, China (GRID:grid.260474.3) (ISNI:0000 0001 0089 5711)
5 Nanjing Medical University, School of Pharmacy, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); State Key Laboratory of Reproductive Medicine, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Key Laboratory of Cardiovascular and Cerebrovascular Medicine, Nanjing, China (GRID:grid.89957.3a)